Abstracts Archive - Page 529 of 2425 - ACR Meeting Abstracts

Abstract Number: 1922 • ACR Convergence 2021
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Raj Sengupta¹, Shruti Narasimham², Borja Mato³, Matic Meglic³, Chiara Perella³, Paula Pamies⁴ and Paul Emery⁵, ¹The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Novartis Ireland Ltd, Dublin, Ireland, Dublin, Ireland, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…
Abstract Number: 1935 • ACR Convergence 2021
Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
Teressa Shaw¹, Wei Zhang², Sara McCoy³, Xueer Qiu¹, Adam Pagenkopf¹, Robert Hal Scofield⁴, Jacques Galipeau³ and Yun Liang¹, ¹University of Wisconsin-Madison, Madison, WI, ²University of California San Diego, La Jolla, CA, ³University of Wisconsin, Madison, WI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Many autoimmune diseases feature increased prevalence in females, with primary Sjögren's syndrome (pSS) being the most female-predominant autoimmune disease with a female-to-male ratio of…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
Abstract Number: 1943 • ACR Convergence 2021
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
Xenofon Baraliakos¹, Effie Pournara², Laura Coates³, Victoria Navarro-Compán⁴, Roisin White⁵, Barbara Schulz² and Robert Landewé⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Xenofon Baraliakos¹, Roberto Ranza², Andrew Ostor³, Francesco Ciccia⁴, Laura Coates⁵, Simona Rednic⁶, Jessica Walsh⁷, Tianming Gao⁸, Apinya Lertratanakul⁸, In-Ho Song⁸, Fabiana Ganz⁸, Kevin Douglas⁸ and Atul Deodhar⁹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ³Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁴University of Campania Luigi Vanvitelli, Napoli, Italy, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸AbbVie Inc., North Chicago, IL, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Michael Linn¹ and Dan Smith², ¹Relapsing Polychondritis Foundation, New York, NY, ²Relapsing Polychondritis Foundation, Canton, MI
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Aberdeen Allen, Colgate Palmolive, Parlin, NJ
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
Abstract Number: PP05 • ACR Convergence 2021
Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
Michael Linn¹, Spenser Mestel² and Susie Ratledge³, ¹Relapsing Polychondritis Foundation, New York, NY, ²New York, NY, ³Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN
Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: PP13 • ACR Convergence 2021
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
Chantelle Marcial, Boston, MA
Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
Abstract Number: 1928 • ACR Convergence 2021
In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

Randy Cron¹, Mingce Zhang¹, Niansheng Chu², Devin Absher³, John Bridges¹, Amanda Schnell¹, Anshul Vagrecha⁴, Shannon Lozinsky⁴, Suchitra Acharya⁴, Carolyn Levy⁴, Winn Chatham¹ and Edward Behrens², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL, ⁴Hofstra/Northwell School of Medicine, Hempstead, NY
Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous missense…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].